You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DONEPEZIL HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for donepezil hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000173 ↗ Memory Impairment Study (Mild Cognitive Impairment Study) Completed Alzheimer's Disease Cooperative Study (ADCS) Phase 3 1999-03-01 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00000173 ↗ Memory Impairment Study (Mild Cognitive Impairment Study) Completed National Institute on Aging (NIA) Phase 3 1999-03-01 The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00004807 ↗ Study of the Pathogenesis of Rett Syndrome Completed Johns Hopkins University N/A 1995-01-01 OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00004807 ↗ Study of the Pathogenesis of Rett Syndrome Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A 1995-01-01 OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00006349 ↗ Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 3 2001-02-01 RATIONALE: Donepezil and vitamin E may be able to decrease side effects caused by radiation therapy given to prevent brain metastases in patients with small cell lung cancer. It is not yet known if donepezil and vitamin E are effective in preventing side effects caused by radiation therapy to the head. PURPOSE: Randomized phase III trial to determine the effectiveness of donepezil and vitamin E in preventing side effects caused by radiation therapy given to prevent brain metastases in patients who have small cell lung cancer.
NCT00006349 ↗ Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed Alliance for Clinical Trials in Oncology Phase 3 2001-02-01 RATIONALE: Donepezil and vitamin E may be able to decrease side effects caused by radiation therapy given to prevent brain metastases in patients with small cell lung cancer. It is not yet known if donepezil and vitamin E are effective in preventing side effects caused by radiation therapy to the head. PURPOSE: Randomized phase III trial to determine the effectiveness of donepezil and vitamin E in preventing side effects caused by radiation therapy given to prevent brain metastases in patients who have small cell lung cancer.
NCT00006399 ↗ Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease Completed Alzheimer's Association Phase 2 1999-09-01 The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for donepezil hydrochloride

Condition Name

Condition Name for donepezil hydrochloride
Intervention Trials
Alzheimer's Disease 87
Alzheimer Disease 46
Healthy 21
Dementia 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for donepezil hydrochloride
Intervention Trials
Alzheimer Disease 163
Dementia 51
Cognitive Dysfunction 37
Cognition Disorders 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for donepezil hydrochloride

Trials by Country

Trials by Country for donepezil hydrochloride
Location Trials
United States 783
Japan 171
Canada 96
Germany 67
Korea, Republic of 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for donepezil hydrochloride
Location Trials
California 54
Florida 51
New York 43
Texas 40
Arizona 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for donepezil hydrochloride

Clinical Trial Phase

Clinical Trial Phase for donepezil hydrochloride
Clinical Trial Phase Trials
Phase 4 71
Phase 3 51
Phase 2/Phase 3 5
[disabled in preview] 177
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for donepezil hydrochloride
Clinical Trial Phase Trials
Completed 213
Terminated 37
Recruiting 23
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for donepezil hydrochloride

Sponsor Name

Sponsor Name for donepezil hydrochloride
Sponsor Trials
Pfizer 31
Eisai Inc. 24
Eisai Co., Ltd. 11
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for donepezil hydrochloride
Sponsor Trials
Other 233
Industry 229
NIH 38
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.